This page shows Alvotech (ALVOW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scale-up is delivering accounting breakeven, but cash still trails profit as growth keeps consuming working capital.
By FY2025, net income turned positive at$27.9M while operating cash flow stayed-$50.2M . The missing cash is visible in inventory-heavy working capital: inventory reached$220.1M after standing at$74.4M in FY2023, so reported profit arrived before the business became fully cash-generative.
Short-term liquidity looks better than the deeper capital structure. The current ratio improved to 1.9x, but negative equity of
This is not yet a self-funding operation. In FY2025, free cash flow was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Alvotech's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Alvotech's revenue surged 19.7% year-over-year to $586.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Alvotech's current ratio of 1.89 indicates adequate short-term liquidity, earning a score of 34/100. The company can meet its near-term obligations, though with limited headroom.
While Alvotech generated -$50.2M in operating cash flow, capex of $64.5M consumed most of it, leaving -$114.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Alvotech passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Alvotech generates $-1.80 in operating cash flow (-$50.2M OCF vs $27.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Alvotech generated $586.3M in revenue in fiscal year 2025. This represents an increase of 19.7% from the prior year.
Alvotech reported $27.9M in net income in fiscal year 2025. This represents an increase of 112.0% from the prior year.
Cash & Balance Sheet
Alvotech generated -$114.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 60.5% from the prior year.
Alvotech held $172.4M in cash against $138.0M in long-term debt as of fiscal year 2025.
Alvotech had 312M shares outstanding in fiscal year 2025. This represents an increase of 3.4% from the prior year.
Margins & Returns
Alvotech's net profit margin was 4.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 52.1 percentage points from the prior year.
Capital Allocation
Alvotech invested $64.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 20.1% from the prior year.
ALVOW Income Statement
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ALVOW Balance Sheet
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B+6.8% | $1.4B+14.0% | $1.2B+14.3% | $1.1B+12.5% | $950.1M+4.3% | $910.7M+9.9% | $828.4M+38.5% | $598.0M |
| Current Assets | $574.0M+12.7% | $509.5M+12.0% | $455.0M+59.5% | $285.2M+46.4% | $194.8M-8.1% | $211.9M-8.2% | $230.7M+92.6% | $119.8M |
| Cash & Equivalents | $172.4M+13.8% | $151.5M+194.5% | $51.4M+369.9% | $10.9M-1.9% | $11.2M-81.5% | $60.5M-9.0% | $66.4M+278.4% | $17.6M |
| Inventory | $220.1M+41.5% | $155.5M+21.6% | $127.9M+32.4% | $96.6M+29.7% | $74.4M-6.2% | $79.4M+11.0% | $71.5M+83.0% | $39.1M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $16.3M-50.5% | $33.0M | N/A |
| Goodwill | $12.8M+0.4% | $12.8M+12.9% | $11.3M-3.1% | $11.7M-3.0% | $12.1M+1.4% | $11.9M+2.1% | $11.6M-5.9% | $12.4M |
| Total Liabilities | $1.8B+13.1% | $1.6B-4.2% | $1.6B-2.4% | $1.7B-11.1% | $1.9B+35.5% | $1.4B-0.3% | $1.4B+89.9% | $733.6M |
| Current Liabilities | $304.1M+8.7% | $279.7M+44.7% | $193.4M-83.9% | $1.2B+360.8% | $260.9M+17.7% | $221.7M+32.5% | $167.3M+49.6% | $111.8M |
| Long-Term Debt | $138.0M+1.3% | $136.3M+21.5% | $112.1M-8.0% | $121.9M+15.4% | $105.6M+20.8% | $87.4M+147.2% | $35.4M-69.2% | $114.8M |
| Total Equity | -$284.5M-64.1% | -$173.3M+58.0% | -$412.8M+31.9% | -$605.9M+35.0% | -$932.5M-94.9% | -$478.5M+15.2% | -$564.4M-316.2% | -$135.6M |
| Retained Earnings | -$2.4B-5.0% | -$2.3B+5.8% | -$2.4B-3.3% | -$2.4B-7.0% | -$2.2B-26.7% | -$1.7B-5.3% | -$1.7B-45.0% | -$1.1B |
ALVOW Cash Flow Statement
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ALVOW Financial Ratios
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 1.89+0.1 | 1.82-0.5 | 2.35+2.1 | 0.24-0.5 | 0.75-0.2 | 0.96-0.4 | 1.38+0.3 | 1.07 |
| Debt-to-Equity | -0.49+0.3 | -0.79-0.5 | -0.27-0.1 | -0.20-0.1 | -0.11+0.1 | -0.18-0.1 | -0.06+0.8 | -0.85 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$284.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Frequently Asked Questions
What is Alvotech's annual revenue?
Alvotech (ALVOW) reported $586.3M in total revenue for fiscal year 2025. This represents a 19.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Alvotech's revenue growing?
Alvotech (ALVOW) revenue grew by 19.7% year-over-year, from $489.7M to $586.3M in fiscal year 2025.
Is Alvotech profitable?
Yes, Alvotech (ALVOW) reported a net income of $27.9M in fiscal year 2025, with a net profit margin of 4.8%.
How much debt does Alvotech have?
As of fiscal year 2025, Alvotech (ALVOW) had $172.4M in cash and equivalents against $138.0M in long-term debt.
What is Alvotech's net profit margin?
Alvotech (ALVOW) had a net profit margin of 4.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Alvotech's free cash flow?
Alvotech (ALVOW) generated -$114.7M in free cash flow during fiscal year 2025. This represents a 60.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Alvotech's operating cash flow?
Alvotech (ALVOW) generated -$50.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Alvotech's total assets?
Alvotech (ALVOW) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Alvotech's capital expenditures?
Alvotech (ALVOW) invested $64.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Alvotech's current ratio?
Alvotech (ALVOW) had a current ratio of 1.89 as of fiscal year 2025, which is generally considered healthy.
What is Alvotech's debt-to-equity ratio?
Alvotech (ALVOW) had a debt-to-equity ratio of -0.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Alvotech's return on assets (ROA)?
Alvotech (ALVOW) had a return on assets of 1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Alvotech's cash runway?
Based on fiscal year 2025 data, Alvotech (ALVOW) had $172.4M in cash against an annual operating cash burn of $50.2M. This gives an estimated cash runway of approximately 41 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Alvotech's debt-to-equity ratio negative or unusual?
Alvotech (ALVOW) has negative shareholder equity of -$284.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Alvotech's Piotroski F-Score?
Alvotech (ALVOW) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Alvotech's earnings high quality?
Alvotech (ALVOW) has an earnings quality ratio of -1.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Alvotech?
Alvotech (ALVOW) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.